Sign in

CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
464600503
Phone
617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
  1. DEFA14A Proxy Proxy Materials
  2. DEF 14A Proxy Proxy Statement
  3. 4 Open-market sale Chief Financial Officer sold 10,896 shares at $3.47 ($37,806)
  4. 4 Open-market sale Chief Medical Officer sold 12,425 shares at $3.47 ($43,082)
  5. 4 Open-market sale Chief Legal Officer sold 9,192 shares at $3.48 ($31,954)
  6. 4 Open-market sale Co-Chief Executive Officer sold 21,490 shares at $3.47 ($74,482)
  7. 4 Open-market sale Co-Chief Executive Officer sold 21,490 shares at $3.46 ($74,454)
  8. EFFECT Other Notice of Effectiveness
  9. CORRESP Other Correspondence Between Filers and SEC Staff
  10. 4 Open-market buy Director bought 10,000 shares at $3.70 ($37,005)
  11. 4 Grant or award Chief Legal Officer acquired 63,851 shares (grant or award)
  12. 4 Grant or award Chief Medical Officer acquired 68,420 shares (grant or award)
  13. 4 Grant or award Co-Chief Executive Officer acquired 180,118 shares (grant or award)
  14. 4 Grant or award Co-Chief Executive Officer acquired 180,118 shares (grant or award)
  15. 4 Grant or award Chief Financial Officer acquired 68,420 shares (grant or award)
  16. UPLOAD Other SEC-generated Letter
  17. 4 Open-market sale Co-Chief Executive Officer sold 4,595 shares at $3.15 ($14,483)
  18. 4 Open-market sale Co-Chief Executive Officer sold 4,595 shares at $3.17 ($14,549)
  19. 4 Open-market sale Chief Legal Officer sold 1,611 shares at $3.12 ($5,022)
  20. S-8 Other Securities Offered to Employees in Benefit Plans

Page 8 of 23 · 446 filings